American Journal of Obstetrics & Gynecology
Volume 199, Issue 5 , Pages 539.e1-539.e6, November 2008

Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies

  • Steven C. Plaxe, MD

      Affiliations

    • Division of Gynecologic Oncology, University of California, San Diego, San Diego, CA
    • ,
  • Sandra E. Brooks, MD

      Affiliations

    • Division of Cancer Prevention and Gynecologic Oncology, Norton Cancer Institute Louisville, KY
    • ,
  • Chunquiao Tian, MS

      Affiliations

    • Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY
    • Corresponding Author InformationReprints: Ms Denise Mackey, GOG, Administrative Office, Four Penn Center, 1600 JKF Blvd, Suite 1020, Philadelphia, PA 19102
    • ,
  • Jeffrey D. Bloss, MD

      Affiliations

    • Genetech, Inc, South San Francisco, CA
    • ,
  • David H. Moore, MD

      Affiliations

    • Gynecologic Oncology of Indiana, Indianapolis, IN
    • ,
  • Harry J. Long, MD

      Affiliations

    • Department of Medical Oncology, Mayo Clinic, Rochester, MN

Received 21 September 2007; received in revised form 28 January 2008; accepted 17 April 2008. published online 20 June 2008.

Objective

This study was undertaken to compare toxicity and outcomes from cisplatin-based combination chemotherapy for black and white women with advanced /recurrent cervical cancer.

Study Design

Frequencies of grade 3 and 4 toxicities, response, and survival were compared by race using data from 3 Gynecologic Oncology Group studies.

Results

Black women experienced significantly less grade 3 and 4 neutropenia (63% vs 82%), leukopenia (58% vs 79%), thrombocytopenia (10% vs 23%), and adverse events of any nature (84% vs 93%) compared with white women. Black patients were not at increased risk of disease progression (adjusted relative risk, 1.11; 95% confidence interval, 0.88-1.38; P = .382) or death (adjusted relative risk, 1.02; 95% confidence interval, 0.82-1.26; P = .893).

Conclusion

Cisplatin-based chemotherapy delivered in a protocol setting for advanced/recurrent carcinoma of the cervix appears better tolerated by black women.

Key words: cervical cancer, chemotherapy, race

 

 This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical and Data Center (CA 37517).

 Cite this article as: Plaxe SC, Brooks SE, Tian C, et al. Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies. Am J Obstet Gynecol 2008;199:539.e1-539.e6.

PII: S0002-9378(08)00434-1

doi:10.1016/j.ajog.2008.04.038

American Journal of Obstetrics & Gynecology
Volume 199, Issue 5 , Pages 539.e1-539.e6, November 2008